COMMUNIQUÉS West-GlobeNewswire

Algernon Announces Pricing of Prospectus Offering
06/09/2019
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (“ Algernon ” or “ Company [...]
Opthea Presents Positive Data from OPT-302 Phase 2b Wet AMD Trial at EURETINA Congress
06/09/2019
MELBOURNE, Australia, Sept. 06, 2019 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical biopharmaceutical company developing novel biologic therapies for eye diseases, announced today that new clinical data from [...]
Myovant Sciences’ Founding Shareholder Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create a Broad Strategic Alliance
06/09/2019
Roivant’s ownership interest in Myovant Sciences (approximately 46% of shares issued and outstanding) to be fully assumed by a new entity, Sumitomo Dainippon-Roivant Alliance, which will be wholly owned by Sumitomo [...]
BrainStorm Cell Therapeutics to Present Late Breaking News ePoster at the 35th ECTRIMS Congress
06/09/2019
NEW YORK, Sept. 06, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in the development of innovative autologous cellular therapies for highly debilitating neurodegenerative diseases [...]
European Commission approves Roche’s Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer
06/09/2019
Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the first and only cancer immunotherapy approved by the European Medicines Agency for the initial treatment of extensive-stage small cell lung [...]
European Commission approves Roche’s new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer
06/09/2019
The approval of the new Tecentriq-based combination expands treatment options for people across Europe affected by non-squamous non-small cell lung cancer (NSCLC) Decision based on data showing that the Tecentriq plus [...]
SunGen Pharma Receives Seventh ANDA Approval from US FDA
06/09/2019
PRINCETON, N.J., Sept. 05, 2019 (GLOBE NEWSWIRE) -- SunGen Pharma, a privately held specialty pharmaceutical company which develops, contract manufactures, and sells pharmaceutical finished products, today announced it [...]
Turning Point Therapeutics Announces Pricing of Public Offering of Common Stock
06/09/2019
SAN DIEGO, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced the pricing of its [...]
Ascent Industries Provides Bi-Weekly Default Status Report
06/09/2019
VANCOUVER, British Columbia, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Ascent Industries Corp. ( CSE: ASNT ) (“ Ascent ” or the “ Company ”) is providing this bi-weekly default status report in accordance with National Policy [...]
Zealand Pharma major shareholder announcement: Van Herk Investments
05/09/2019
Company announcement – No. 31 / 2019 Zealand Pharma major shareholder announcement: Van Herk Investments Copenhagen, September 5, 2019 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen- [...]
President & CEO of Nova Leap Health Corp. to Present at the 12th Annual LD Micro Main Event
05/09/2019
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Sept. 05, 2019 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a 2019 [...]
Veloxis Increases Share Capital in Connection with Exercise of Warrants
05/09/2019
Company Release no. 15/2019 To: NASDAQ Copenhagen A/S Copenhagen, Denmark, 05 September 2019 Veloxis Increases Share Capital in Connection with Exercise of Warrants Veloxis Pharmaceuticals A/S announces that the Company [...]
Rockwell Medical, Inc. Appoints Industry Veteran John P. McLaughlin to Board of Directors
05/09/2019
WIXOM, Mich., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the "Company"), a biopharmaceutical company dedicated to improving outcomes for patients with anemia, with an [...]
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program
05/09/2019
CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the recipients of Route 79, The Duchenne [...]
Neoleukin Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/09/2019
SEATTLE, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc. (“Neoleukin”) (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, [...]
Caladrius Biosciences to Participate at the Upcoming September Conferences
05/09/2019
BASKING RIDGE, N.J., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements [...]
Microbot Medical to Demonstrate a Working Prototype of its Self-Cleaning Shunt at the Rodman & Renshaw Annual Global Investment Conference
05/09/2019
HINGHAM, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- At the upcoming Rodman & Renshaw Global Investment Conference, Harel Gadot, CEO, President and Chairman of Microbot Medical Inc. (Nasdaq: MBOT), will demonstrate a [...]
Trevi Therapeutics to Participate in Panel Discussion at BTIG Pain / Pruritus Management Forum
05/09/2019
NEW HAVEN, Conn., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious [...]
Avid Bioservices Reports Financial Results for First Quarter Fiscal 2020 and Recent Developments
05/09/2019
-- Achieved First Quarter Revenue of $15.3 Million; Reaffirms Fiscal 2020 Projected Revenue of $64 to $67 Million -- -- Signed Two Contract Manufacturing Agreements with New and Existing Customers -- TUSTIN, Calif., [...]

Pages